The Role of Hypoxia in Radio-and Immunotherapy Sensitivity

Register to watch the recording here:

Dr Paul Span
Associate Professor at the Radiotherapy & OncoImmunology (ROI) laboratory,
Radboud University Medical Center, Nijmegen, Netherlands

Dr Paul Span is an associate professor at the Radiotherapy & OncoImmunology (ROI) laboratory (dept. Radiation Oncology, Radboudumc, Nijmegen). His group focusses on mechanisms of insensitivity to radiotherapy (radioresistance), combining preclinical research with clinical validation in various cancer patient cohorts. These radiobiological projects explore a range of potential causes of radioresistance, from the tumor (micro)environment (hypoxia, autophagy, metabolism), genomic instability (APOBEC), to off-target effects of endocrine treatment (tamoxifen). Paul has been chair of the PathoBiology Group (PBG) of the European Organisation for Research and Treatment of Cancer (EORTC), and of the Women’s Cancers research theme of the Radboudumc. Currently, he is a member of the Scientific Advisory Group Radiobiology 2023/2025 and Biology committee of the European SocieTy of Radiation Oncology (ESTRO), and board member of the Dutch Society of Radiobiology (NVRB).

Event hosted and organised by Don Whitley Scientific Limited.